Connor J R, Dodds R A, James I E, Gowen M
SmithKline Beecham Pharmaceuticals, Department of Cellular Biochemistry, King of Prussia, Pennsylvania 19406, USA.
J Histochem Cytochem. 1995 Dec;43(12):1193-201. doi: 10.1177/43.12.8537635.
Animal model and in vitro cultures suggest that osteoclasts and cells of the mononuclear phagocyte system share a common precursor. However, the human osteoclast precursor has not been positively identified. We attempted to identify the precursor in situ by using a number of osteoclast- and macrophage-selective markers, together with the expression of osteopontin mRNA, previously shown to be abundant in human osteoclasts. Sections of osteophytic bone and a panel of inflammatory connective tissues were processed for in situ hybridization; serial sections were analyzed for tartrate-resistant acid phosphatase (TRAP) and nonspecific esterase (NSE) activity, selective cytochemical markers for the osteoclast and cells of the macrophage/monocyte lineage, respectively. The murine anti-human osteoclast monoclonal antibodies 23C6 (vitronectin receptor) and C35 (osteoclast-selective) were used to further identify the osteoclast phenotype. We compared osteoclasts, giant cells, and their respective putative mononuclear precursors. At resorption sites within osteophytic bone, osteopontin mRNA was expressed in osteoclasts and a distinct population of TRAP+, NSE- mononuclear cells. Adjacent clusters of mononuclear cells were TRAP- and NSE+ or were active for both enzymes; these cells demonstrated variable expression of osteopontin mRNA. In the inflammatory connective tissues, abundant macrophage-like cells (NSE+/TRAP-) did not express osteopontin mRNA. However, TRAP+ mononuclear cells observed among clusters of NSE+ cells did express osteopontin mRNA. At these sites, clusters of putative macrophage polykaryons removing fragments of bone debris were observed. These giant cells and associated mononuclear cells were NSE- and distinctly TRAP+, and expressed osteopontin mRNA, C35, and 23C6 (human osteoclast) reactivity. Therefore, cells involved in the remodeling (resorption) of bone or the removal of bone debris, together with their immediate precursors, switch from being NSE+/TRAP- to NSE-/TRAP+ cells that express osteopontin mRNA. We propose that the clusters of NSE+/TRAP- mononuclear cells represent the immature osteoclast precursor. In support of this, TRAP+/NSE+ cells were occasionally observed in both tissues, representing an intermediate stage in differentiation. These results further suggest that cells of the mononuclear phagocyte lineage within bone and inflammatory connective tissue have the potential to differentiate into osteoclasts.
动物模型和体外培养表明,破骨细胞与单核吞噬细胞系统的细胞有着共同的前体。然而,人类破骨细胞前体尚未得到确切鉴定。我们试图通过使用多种破骨细胞和巨噬细胞选择性标志物,以及骨桥蛋白mRNA的表达,来原位鉴定前体,此前已证明骨桥蛋白mRNA在人类破骨细胞中大量存在。对骨赘骨切片和一组炎症性结缔组织进行原位杂交处理;对连续切片分析抗酒石酸酸性磷酸酶(TRAP)和非特异性酯酶(NSE)活性,分别为破骨细胞和巨噬细胞/单核细胞系细胞的选择性细胞化学标志物。使用鼠抗人破骨细胞单克隆抗体23C6(玻连蛋白受体)和C35(破骨细胞选择性)进一步鉴定破骨细胞表型。我们比较了破骨细胞、巨细胞及其各自假定的单核前体。在骨赘骨内的吸收部位,骨桥蛋白mRNA在破骨细胞和一群独特的TRAP +、NSE - 单核细胞中表达。相邻的单核细胞簇TRAP - 且NSE +,或两种酶均有活性;这些细胞显示出骨桥蛋白mRNA的可变表达。在炎症性结缔组织中,大量巨噬样细胞(NSE + /TRAP - )不表达骨桥蛋白mRNA。然而,在NSE + 细胞簇中观察到的TRAP + 单核细胞确实表达骨桥蛋白mRNA。在这些部位,观察到假定的巨噬多核细胞簇正在清除骨碎片。这些巨细胞和相关的单核细胞NSE - 且明显TRAP +,并表达骨桥蛋白mRNA、C35和23C6(人类破骨细胞)反应性。因此,参与骨重塑(吸收)或清除骨碎片的细胞及其直接前体,从NSE + /TRAP - 细胞转变为表达骨桥蛋白mRNA的NSE - /TRAP + 细胞。我们提出NSE + /TRAP - 单核细胞簇代表未成熟的破骨细胞前体。作为对此的支持,在两种组织中偶尔观察到TRAP + /NSE + 细胞,代表分化的中间阶段。这些结果进一步表明,骨和炎症性结缔组织内的单核吞噬细胞系细胞有分化为破骨细胞的潜力。